Last reviewed · How we verify
Synthetic neutralising antibodies
Synthetic neutralising antibodies work by binding to and neutralising specific viral proteins, thereby preventing the virus from infecting cells.
Synthetic neutralising antibodies work by binding to and neutralising specific viral proteins, thereby preventing the virus from infecting cells. Used for Prevention of COVID-19.
At a glance
| Generic name | Synthetic neutralising antibodies |
|---|---|
| Also known as | REGEN-COV, casirivimab and imdevimab |
| Sponsor | University of Oxford |
| Drug class | Monoclonal antibody |
| Target | Specific viral proteins (e.g. SARS-CoV-2 spike protein) |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This mechanism of action is based on the principle of immunotherapy, where the antibodies mimic the natural immune response to provide protection against viral infections. By binding to the viral proteins, the antibodies prevent the virus from entering host cells, thereby reducing the severity and duration of the infection.
Approved indications
- Prevention of COVID-19
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV (PHASE1)
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (PHASE1)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synthetic neutralising antibodies CI brief — competitive landscape report
- Synthetic neutralising antibodies updates RSS · CI watch RSS
- University of Oxford portfolio CI